Trial Profile
A Multicenter Phase 1B Pharmacodynamics Study of MRX34, MicroRNA miR-Rx34 Liposomal Injection, in Patients With Advanced Melanoma and Biopsy Accessible Lesions
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs MRX 34 (Primary) ; Dexamethasone; Dexamethasone
- Indications Malignant melanoma
- Focus Biomarker; Pharmacokinetics
- Acronyms MRX34-102
- Sponsors Mirna Therapeutics
- 26 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Aug 2016 New trial record